Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A registrational trial assessing CPL36

Next Previous
Trial Profile

A registrational trial assessing CPL36

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CPL 500036 (Primary)
  • Indications Drug-induced dyskinesia; Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Celon Pharma

Most Recent Events

  • 08 Oct 2025 According to Celon Pharma media release, the company announced that the U.S. Food and Drug Administration (FDA) provided positive feedback clearing the path for Phase 3 testing of CPL'36, the company's novel second-generation PDE10A inhibitor for schizophrenia.
  • 12 Jul 2024 New trial record
  • 09 Jul 2024 According to Celon Pharma media release, management plans to discuss encouraging results from phase 2 trial trial with regulatory agencies to advance CPL36 towards registrational trials and global marketing approvals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top